Poor
Partially Aligned
Patient Risk:
Moderate
Summary
Most non-medication statements (copay/insurance/third-party websites/patient assistance) are not supported by the provided label excerpts. Of the medication-related claims, the indication is broadly directionally consistent with triglyceride lowering but mechanism statements are not fully supported by the provided label excerpt (mechanism is partially described but not the exact claims).
Category Scores
Accurate Statements
Vascepa (icosapent ethyl) is a prescription medication used to lower triglyceride levels in the blood.
Supported directionally: Indications/Usage includes reducing TG levels in adults with severe hypertriglyceridemia (≥500 mg/dL) as an adjunct to diet (Section 1).
Unsupported Statements
Vascepa works by reducing the production of triglycerides in the liver.
Label mechanism excerpt states EPA reduces hepatic VLDL-TG synthesis and/or secretion (Section 12.1), which is related but not identical to 'reducing the production of triglycerides in the liver' as stated; the provided label does not use that exact phrasing.
Vascepa works by increasing the breakdown of existing triglycerides in the bloodstream.
Label excerpt states 'enhances TG clearance from circulating VLDL particles' (Section 12.1); it does not specifically support 'breakdown of existing triglycerides in the bloodstream' as stated.
A copay is a fixed amount of money that a patient pays for a prescription medication.
Not addressed in the provided FDA label excerpts.
The amount of a copay depends on the patient’s insurance plan and the specific medication being taken.
Not addressed in the provided FDA label excerpts.
Some insurance plans may cover Vascepa in full while others may require a copay.
Not addressed in the provided FDA label excerpts.
If a patient has not met their deductible for the year, they may be responsible for paying a higher copay for Vascepa.
Not addressed in the provided FDA label excerpts.
Some insurance plans require patients to pay a percentage of the medication’s cost (coinsurance).
Not addressed in the provided FDA label excerpts.
Vascepa may be listed on an insurance plan’s formulary, which can affect the copay amount.
Not addressed in the provided FDA label excerpts.
DrugPatentWatch.com provides information on prescription medications, including copays and formulary status.
Not addressed in the provided FDA label excerpts.
Some pharmaceutical companies offer patient assistance programs that can help reduce the cost of Vascepa.
Not addressed in the provided FDA label excerpts.
Vascepa is not available in a generic form.
Not addressed in the provided FDA label excerpts.
Contradictions
Important Omissions
The specific labeled indications/limitations are not stated (e.g., adjunct to maximally tolerated statin therapy to reduce risk of MI/stroke/coronary revascularization/unstable angina hospitalization in adults with elevated TG (≥150 mg/dL) with established CVD or diabetes plus risk factors; and adjunct to diet to reduce TG in severe hypertriglyceridemia (≥500 mg/dL)).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several statements are non-label financial/coverage claims not supported by the provided label excerpts, and mechanism statements are not precisely aligned with label language. The only label-aligned statement is general TG lowering; missing indication/limitations could lead to misunderstanding of when Vascepa is indicated.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Medication mechanism statements are not supported verbatim by the provided label excerpt, and most coverage/cost/formulary/generic-form statements are not present in the provided FDA label excerpts.
Suggested Improvement
Limit claims to the provided label: (1) specify labeled indications for TG lowering/adjunct therapy and TG thresholds, and (2) use label-consistent mechanism wording (e.g., reduction of hepatic VLDL-TG synthesis/secretion and enhanced TG clearance from circulating VLDL particles) rather than broader 'production'/'breakdown in the bloodstream' phrasing. Exclude non-label financial/coverage-website/generic-availability claims unless supported by additional label text.